If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.80    0.00 (0.00%)
Bid:
8.60
Ask:
9.00
Spread: 0.40 (4.651%)
Market Cap: £58.32m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Directorate Change

29 Oct 2020 07:00

RNS Number : 5443D
Kromek Group PLC
29 October 2020
 

29 October 2020

 

Kromek Group plc

("Kromek" or the "Group")

 

Directorate Change

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that Mr Derek Bulmer, the current Chief Financial Officer and In-House Counsel, will step down from this role and as a Director of the Group on 31 October 2020. The Board carries out regular and routine succession planning for senior positions, involving both internal and external potential candidates, and Mr Bulmer had indicated his wish to explore possible opportunities outside the Group, after an appropriate handover period with a successor. Whilst disappointed to see Mr Bulmer step down, Kromek is very pleased to announce the appointment of Mr Paul Farquhar as Chief Financial Officer and a Director of the Group with effect from 2 November 2020.

 

Mr Farquhar, aged 58, is a Chartered Accountant with almost 30 years' experience as a finance director and chief financial officer, primarily for international businesses. This includes 10 years as Vice President, Treasurer and Chief Financial Officer of Sevcon Inc, which was a NASDAQ-listed designer, manufacturer and supplier of microprocessor controls for electric and hybrid vehicles through wholly-owned subsidiaries in Europe, North America and Asia and via an international dealer network. Alongside his day-to-day responsibilities as the CFO of a public company, Mr Farquhar oversaw the raising of equity and debt finance and M&A activity. This included the acquisition of a private Italian battery charger manufacturer and the formation, and subsequent successful buy-out, of a joint venture in China. He also established a global finance team in five countries with common financial reporting systems to meet the needs of a growing technology business. During this period, Mr Farquhar oversaw an increase in the Sevcon market value from $50m in 2010 to $200m in 2017 when the company was acquired by BorgWarner Inc.

 

More recently, since leaving Sevcon in 2017, Mr Farquhar has supported a number of SMEs as Finance Director and he is a Non-Executive Director of several community organisations in the North East of England, including City Hospitals Independent Commercial Enterprises Ltd, which is a subsidiary of South Tyneside and Sunderland NHS Foundation Trust that provides services to South Tyneside Hospital and City Hospitals Sunderland. Mr Farquhar began his career as a chartered accountant, spending 10 years as an auditor at Jennings Johnson in Sunderland and at PricewaterhouseCoopers in Newcastle and Lisbon, Portugal.

 

Sir Peter Williams CBE, Chairman of Kromek, said: "It is a measure of our growing reputation as a business that we are able to attract high-quality people to Kromek, and I am delighted to welcome Paul to our Board as CFO. He brings a wealth of experience, having successfully grown a listed business, and is a great addition to our already strong management team. His abilities in establishing global finance teams, equity and debt financing as well as M&A activity, have been well demonstrated throughout his career and we look forward to working with him and to benefitting from his experience."

 

"I would also like to take this opportunity to extend my sincere thanks to the outgoing CFO, Derek Bulmer, for his enormous contribution to the business. As a key member of the senior management team, his work has been integral to Kromek's success to date. He was instrumental in the acquisition of our key US subsidiary and, subsequently, our listing on the London Stock Exchange. Derek has also built robust financial systems and, in addition, he has been heavily involved in the commercial life of the Company, internationally as well as in the UK. His efforts during the challenging times of the ongoing Covid pandemic have been greatly appreciated by the Board and it has been my privilege to work alongside him during my time as Chairman. We wish him every success for the future."

 

Paul Farquhar, incoming CFO, said: "I am delighted to have been appointed CFO of Kromek. The Group has a significant presence in a number of high-growth end-markets and a leading position globally in the manufacture and supply of CZT-based products and solutions. It is great to be joining this fantastic business at such a pivotal time in its development and to take over the baton so expertly carried by Derek. I look forward to working alongside Arnab and the rest of the management team to deliver on our strategic objectives and create value for all shareholders."

 

Derek Bulmer, outgoing CFO, said: "I have truly enjoyed over a decade of working with the team at Kromek. The Group has a pool of extraordinarily talented people and a vast array of technology and products to meet some of the world's most critical problems. I would like to take this opportunity to thank the colleagues with whom I have had the pleasure of working and who have provided so much inspiration. I am incredibly proud of what we have achieved together - from raising equity financing for growth and development of the technology to the expansion into the US and internationally. I leave the finances of the business in the very capable and experienced hands of Paul in order to seek opportunities where I can use my experience and expertise to work with other companies who have interesting technologies and ambitious plans."

 

Other than as set out below, there are no other matters required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies as regards Paul's appointment. Paul Neil Farquhar does not hold any shares in the Group.

 

Regulatory disclosures:

Current directorships

Directorships in the past 5 years

City Hospitals Independent Commercial Enterprises Ltd

Paul Farquhar Consulting & Advisory Ltd

Northern Lights Learning Trust

Sevcon Ltd (now BorgWarner Gateshead Limited)

Community Foundation Serving Tyne and Wear and Northumberland

Sevcon Inc (now Borg Warner Inc)

Tyne & Wear Foundation Ltd

Industrial Capacitors (Wrexham) Ltd (now BorgWarner Wrexham Limited)

 

The FD Centre Limited

 

Mr Farquhar was a director of the Team Valley Links Community Interest Company between 2012 and 2015, which was the subject of a solvent members' voluntary liquidation in 2015 following the withdrawal of funding by the local council.

 

For further information, please contact:

 

Kromek Group plc

 

Sir Peter Williams, Chairman

Arnab Basu, CEO

 

+44 (0)1740 626 060

Cenkos Securities plc (Nominated Adviser and Broker)

 

Max Hartley (NOMAD)

Julian Morse (Sales)

 

+44 (0)20 7397 8900

Luther Pendragon (PR)

 

Harry Chathli

Claire Norbury

Alexis Gore

Joe Quinlan

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over one hundred full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and

https://twitter.com/kromekgroup.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFFFEIISLTFII
Date   Source Headline
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:50 pmRNSHolding(s) in Company
26th Feb 201912:56 pmRNSDirector Dealings
26th Feb 20197:00 amRNSNuclear security contract with new OEM customer
25th Feb 20191:02 pmRNSResults of General Meeting and Open Offer and TVR
7th Feb 20197:00 amRNSFirm Placing and Open Offer and Notice of GM
28th Jan 20197:00 amRNSKromek Awarded $58m Medical Imaging Contract
14th Jan 20197:00 amRNSInterim Results
18th Dec 20187:00 amRNSNotice of Results
10th Dec 20187:00 amRNSKromek awarded first biological contract by DARPA
19th Nov 20187:00 amRNSFive-year $7.8m baggage screening contract
1st Oct 20185:12 pmRNSResult of AGM and Directorate Change
27th Sep 20187:00 amRNSKromek awarded $1.8m funding from DTRA
7th Sep 20182:57 pmRNSNotice of AGM and Posting of Annual Report
20th Aug 20187:00 amRNSKromek wins two new contracts in medical division
23rd Jul 20187:00 amRNSKromek secures two contracts from US government
17th Jul 20187:00 amRNSKromek radiation detectors used during NATO Summit
2nd Jul 20187:00 amRNSFinal Results
30th May 20187:00 amRNSFive-year contract from existing medical customer
1st May 20187:00 amRNSTrading Update
23rd Apr 20187:00 amRNSAward of Molecular Breast Imaging Device project
12th Mar 20187:00 amRNSAward of $1.6m extension to contract by DARPA
11th Jan 20187:00 amRNSAppointment of Joint Broker
19th Dec 20177:00 amRNSInterim Results
27th Nov 20177:00 amRNSNotice of Results
31st Oct 20174:13 pmRNSTotal Voting Rights
13th Oct 20177:00 amRNSDirector/PDMR Shareholding
10th Oct 20179:50 amRNSDirector/PDMR Shareholding
26th Sep 201712:12 pmRNSResult of AGM
26th Sep 20177:00 amRNSDirectorate Change
19th Sep 20174:43 pmRNSExercise of Options
4th Sep 20177:00 amRNSNew five-year security screening contract
1st Sep 201710:49 amRNSNotice of AGM and Posting of Annual Report
31st Aug 201710:51 amRNSTotal Voting Rights
17th Aug 20177:00 amRNSAward of Five-Year Contract from BMD Customer
10th Jul 201712:00 pmRNSPublication of Annual Report
28th Jun 20177:00 amRNSFinal Results
12th Jun 20177:00 amRNSKromek Radiation Detectors Used During Trump Visit
1st Jun 20171:34 pmRNSTotal Voting Rights
2nd May 201712:23 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSTrading Update
5th Apr 201712:18 pmRNSBlock listing Interim Review
29th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20177:00 amRNSAward of New Contract for Radiation Detectors
22nd Feb 20177:00 amRNSFive-Year Contract in Security Screening Market
15th Feb 20174:35 pmRNSHolding(s) in Company
15th Feb 201712:54 pmRNSHolding(s) in Company
15th Feb 201712:51 pmRNSHolding(s) in Company
14th Feb 20175:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.